Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Business Update and Financing

4 May 2020 07:00

RNS Number : 7387L
Premier Veterinary Group PLC
04 May 2020
 

 

 

PREMIER VETERINARY GROUP PLC

 

("PVG", the "Company" or the "Group")

 

Business Update and Financing

 

 

London, UK, 4 May 2020 - Premier Veterinary Group PLC (LSE: PVG)

Business Update

The unaudited consolidated management accounts for the six months ended 31 March 2020 show a 5.2% increase in revenues to £1,965,000 (31 March 2019: £1,867,000) and a significant improvement in the group's loss from operations before interest and tax to £(842,000) (31 March 2019 £(1,390,000)).

For the same period PVG achieved a 22% increase in the number of revenue generating pets on active plans to 336,000 (31 March 2019: 275,000).

As part of the continual development of functionality within its integrated multi-currency platform, PVG launched a home delivery offering in the UK during April 2018 (branded as Post2Pet™). The service has been particularly well received by clinics and pet owners alike following the Government lock-down announced on 23 March 2020. Post2Pet™ has enabled the continued supply of important medicines to pet owners during this period when limitations have been imposed on veterinary clinics and the movement of people.

Notwithstanding the impact of the Coronavirus (Covid-19) pandemic on PVG's business (which may result in slower growth and increased cancellations by pet owners) revenues for the month of April 2020 were 1.8% higher than February (being the last full month prior to the UK lockdown) and the number of pets on plan increased slightly during this period.

 

In view of the global uncertainties PVG has considered the assistance available from government agencies in the UK, US and France and has accessed that assistance where appropriate including the furloughing of a small number of employees. PVG's remaining employees including the directors have agreed to a Group wide reduction in salaries from April to June and other short-term cost savings have been implemented.

Financing

Bybrook Finance Solutions Limited (BFSL) has provided loan finance to PVG pursuant to a facility agreement dated 25 January 2019 (as amended by a supplemental deed of amendment dated 23 December 2019 and a second supplemental deed of amendment dated 29 January 2020) (the 2019 Facility) and a facility agreement dated 29 January 2020 (the 2020 Facility).

The 2020 Facility provided for loan finance of £1.1m of which £600,000 was drawn down in January 2020 with a repayment date of 30 April 2020. The draw-down of the remaining facility and the extension of the repayment date to 31 July 2021 was subject to the issue by PVG of warrants to subscribe for up to 383,673 new PVG ordinary shares of 10p each at an exercise price of 10p per share within 5 years of the issue of any such warrants (the Warrants). As a result of the occurrence of the Coronavirus (Covid-19) pandemic and the imposition of a lock down by the UK Government PVG's Annual General Meeting due to take place on 31 March 2020 was postponed and the Warrants could not be issued because PVG did not have a valid authority to issue shares. Accordingly the repayment date was not extended and BFSL no longer has an obligation to make any further advances to PVG under the 2020 Facility.On 1 May 2020 PVG and BFSL entered into further deeds of amendment that provide for (i) the waiver of events of default that have occurred under the 2019 Facility and the 2020 Facility as a result of actions taken by PVG in light of the Coronavirus (Covid-19) pandemic and (ii) the extension of the repayment date in the 2020 Facility to 31 July 2021.

Rajan Uppal the sole director and shareholder of BFSL is a director of PVG and has an interest in 5,421,138 Ordinary Shares in PVG representing 35.3% of PVG's issued share capital.

Crossroads Finance limited ("Crossroads"), a company jointly owned and controlled by Dominic Tonner, Chief Executive Officer of PVG, and his spouse has provided funding to BFSL linked to BFSL's loans to PVG.

Dominic Tonner has an interest in 1,799,670 Ordinary Shares in PVG, representing 11.73% of PVG's issued share capital.

Annual General Meeting (AGM)

PVG continues to review options for holding the AGM as soon as is practically and safely possible and we anticipate further guidance from the Department for Business, Energy and Industrial Strategy and the Financial Reporting Council to provide clarity in that regard with new legislation to allow an AGM to proceed.

Outlook

The Coronavirus (Covid-19) pandemic has created uncertainties which make it more difficult for many businesses including PVG to forecast with any degree of certainty. However the directors of PVG believe that the nature of PVG's business and its continued willingness to invest in its technology platform and people even in these difficult times will lead to continued albeit slower growth and that PVG has sufficient working capital for the foreseeable future.

 

-Ends-

 

For further information, please contact:

 

Premier Veterinary Group plc

Dominic Tonner, Chief Executive Officer Tel: +44 (0)117 970 4130

Andrew Paull, Chief Financial Officer

 

For further details go to: www.premiervetgroup.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDZZGGKNFZGGZM
Date   Source Headline
21st Feb 20117:00 amRNSBoard Change
11th Feb 20117:00 amRNSNotice of Results
8th Feb 20117:00 amRNSDisposal of Majority of Woundcare Business
20th Jan 201112:25 pmRNSHolding(s) in Company
4th Jan 20111:19 pmRNSTotal Voting Rights
16th Dec 20107:00 amRNSChange of Adviser
6th Dec 20109:40 amRNSBlocklisting Interim Review
29th Nov 20101:06 pmRNSHolding(s) in Company
29th Nov 20107:00 amRNSPositive results for pre-clinical product EG013
11th Nov 20107:00 amRNSInterim Management Statement
8th Nov 20102:21 pmRNSHolding(s) in Company
23rd Sep 20104:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20104:35 pmRNSPrice Monitoring Extension
14th Sep 20104:21 pmRNSHolding(s) in Company
14th Sep 20104:19 pmRNSHolding(s) in Company
13th Sep 20103:29 pmRNSDirector/PDMR Shareholding
9th Sep 20107:00 amRNSStrategic Review
31st Aug 201010:33 amRNSTotal Voting Rights
27th Aug 201010:08 amRNSForm 8.5 (EPT/NON-RI)
25th Aug 20107:00 amRNSHalf Yearly Report
20th Aug 20102:27 pmPRNForm 8.3 - Ark Therapeutics Group Plc
19th Aug 201011:35 amRNSForm 8.5 (EPT/NON-RI)
16th Aug 201012:29 pmRNSForm 8.3 - Ark Therapeutics Group plc
16th Aug 20107:00 amRNSForm 8.3 - Ark Therapeutics PLC (Amendment)
13th Aug 20104:24 pmRNSRe EGM
13th Aug 201011:34 amRNSForm 8.5 (EPT/NON-RI)
13th Aug 201011:22 amRNSForm 8.5 (EPT/RI)
13th Aug 201010:30 amRNSForm 8.3 - Ark Therapeutics PLC
11th Aug 201011:35 amRNSForm 8.3 - [Ark Therapeutics Plc]
5th Aug 201012:31 pmRNSForm 8.3 - Ark Therapeutics Group PLC
4th Aug 20104:41 pmRNSSecond Price Monitoring Extn
4th Aug 20104:35 pmRNSPrice Monitoring Extension
4th Aug 201010:00 amRNSForm 8.3 - Ark Therapeutics Group
3rd Aug 201010:47 amRNSForm 8.3 - Ark Therapeutics
30th Jul 201011:22 amRNSForm 8.3 - Ark Therapeutics Plc
29th Jul 201010:34 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 201011:03 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 201010:36 amRNSHolding(s) in Company
28th Jul 201010:30 amRNSForm 8.3 - Ark Therapeutics
28th Jul 201010:01 amRNSHolding(s) in Company
26th Jul 20102:57 pmRNSForm 8.3 - [Ark Therapeutics]
26th Jul 20102:41 pmPRNForm 8.3 - ARK THERAPEUTICS
26th Jul 201011:37 amRNSForm 8.5 (EPT/NON-RI)
23rd Jul 201011:57 amRNSForm 8.5 (EPT/NON-RI)
23rd Jul 201011:15 amRNSForm 8.3 - Ark Therapeutics Group plc
22nd Jul 20102:34 pmPRNForm 8.3 - Ark Theraputics Plc
22nd Jul 201012:54 pmRNSForm 8.3 - Ark Therapeutics Group plc
22nd Jul 201011:19 amRNSForm 8.5 (EPT/NON-RI)
22nd Jul 201010:55 amRNSForm 8.3 - Ark Therapeutics Group Plc
21st Jul 20102:41 pmRNSForm 8.3 - Ark Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.